166 related articles for article (PubMed ID: 23250130)
21. Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis.
Fox RJ; Mehta R; Pham T; Park J; Wilson K; Bonafede M
BMC Neurol; 2022 Jun; 22(1):211. PubMed ID: 35672686
[TBL] [Abstract][Full Text] [Related]
22. Treatment selection and experience in multiple sclerosis: survey of neurologists.
Hanson KA; Agashivala N; Wyrwich KW; Raimundo K; Kim E; Brandes DW
Patient Prefer Adherence; 2014; 8():415-22. PubMed ID: 24729689
[TBL] [Abstract][Full Text] [Related]
23. Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data.
Earla JR; Paranjpe R; Kachru N; Hutton GJ; Aparasu RR
Res Social Adm Pharm; 2020 Dec; 16(12):1670-1676. PubMed ID: 32171597
[TBL] [Abstract][Full Text] [Related]
24. Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis.
Li P; Ladage VP; Berger J; Chahin S; Jhaveri M; Geremakis C; Doshi JA
Value Health; 2020 Mar; 23(3):328-334. PubMed ID: 32197728
[TBL] [Abstract][Full Text] [Related]
25. Laboratory Monitoring Practices Among Canadian Multiple Sclerosis Clinicians.
Atwal A; Schabas A; Head J; Taylor C; Traboulsee A; Barclay K; Carruthers R
Can J Neurol Sci; 2019 Jul; 46(4):389-393. PubMed ID: 31111800
[TBL] [Abstract][Full Text] [Related]
26. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
[TBL] [Abstract][Full Text] [Related]
27. The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022.
Zhao T; Taylor BV; Campbell JA; Palmer AJ
Mult Scler; 2024 Jan; 30(1):80-88. PubMed ID: 38116594
[TBL] [Abstract][Full Text] [Related]
28. Prescribing for multiple sclerosis patients in general practice: a case-control study.
Tremlett HL; Luscombe DK; Wiles CM
J Clin Pharm Ther; 2001 Dec; 26(6):437-44. PubMed ID: 11722681
[TBL] [Abstract][Full Text] [Related]
29. Influences on the start, selection and duration of treatment with antibiotics in long-term care facilities.
Daneman N; Campitelli MA; Giannakeas V; Morris AM; Bell CM; Maxwell CJ; Jeffs L; Austin PC; Bronskill SE
CMAJ; 2017 Jun; 189(25):E851-E860. PubMed ID: 28652480
[TBL] [Abstract][Full Text] [Related]
30. Opioid Prescribing Patterns and Complications in the Dermatology Medicare Population.
Cao S; Karmouta R; Li DG; Din RS; Mostaghimi A
JAMA Dermatol; 2018 Mar; 154(3):317-322. PubMed ID: 29417134
[TBL] [Abstract][Full Text] [Related]
31. Progressive trends in the prevalence of benzodiazepine prescribing in older people in Ontario, Canada.
Tu K; Mamdani MM; Hux JE; Tu JB
J Am Geriatr Soc; 2001 Oct; 49(10):1341-5. PubMed ID: 11890493
[TBL] [Abstract][Full Text] [Related]
32. Disparities in DMT treatment: Demographic and neurocognitive differences between MS patients currently treated versus not treated with disease-modifying therapies.
Leavitt VM; Dworkin JD; Galioto R; Ratzan AS
Mult Scler Relat Disord; 2024 May; 85():105508. PubMed ID: 38452646
[TBL] [Abstract][Full Text] [Related]
33. UK variance in DMT advice and prescribing in MS and pregnancy: Impact of the UK consensus on pregnancy in multiple sclerosis ABN guidelines.
Yam C; Rog D; Ford H; Murray K; Hughes S; Pearson O; Brex P; Dobson R
Mult Scler Relat Disord; 2021 Nov; 56():103272. PubMed ID: 34614458
[TBL] [Abstract][Full Text] [Related]
34. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.
Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ
J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144
[TBL] [Abstract][Full Text] [Related]
35. Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.
Setayeshgar S; Kingwell E; Zhu F; Zhang T; Carruthers R; Marrie RA; Evans C; Tremlett H
Mult Scler Relat Disord; 2019 Jan; 27():364-369. PubMed ID: 30476872
[TBL] [Abstract][Full Text] [Related]
36. Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database.
Kawachi I; Okamoto S; Sakamoto M; Ohta H; Nakamura Y; Iwasaki K; Yoshida M; Hiroi S; Ogino M
BMC Neurol; 2019 Dec; 19(1):324. PubMed ID: 31842786
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
38. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Hartung DM; Bourdette DN; Ahmed SM; Whitham RH
Neurology; 2015 May; 84(21):2185-92. PubMed ID: 25911108
[TBL] [Abstract][Full Text] [Related]
39. Patient awareness about family planning represents a major knowledge gap in multiple sclerosis.
Rasmussen PV; Magyari M; Moberg JY; Bøgelund M; Jensen UFA; Madsen KG
Mult Scler Relat Disord; 2018 Aug; 24():129-134. PubMed ID: 30005355
[TBL] [Abstract][Full Text] [Related]
40. Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.
Setayeshgar S; Kingwell E; Zhu F; Zhang X; Zhang T; Marrie RA; Carruthers R; Tremlett H
Mult Scler Relat Disord; 2018 Oct; 25():57-60. PubMed ID: 30036855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
